Clinical experience with immunotherapy in patients with diffuse intrinsic pontine glioma.

IF 1.6 4区医学 Q3 PHARMACOLOGY & PHARMACY

European journal of hospital pharmacy : science and practice Pub Date : 2025-02-21 DOI:10.1136/ejhpharm-2022-003511

Mónica Gasanz Garicochea, Isabel Martínez-Romera, Marta Pilar Osuna-Marco, Blanca López-Ibor Aliño

{"title":"Clinical experience with immunotherapy in patients with diffuse intrinsic pontine glioma.","authors":"Mónica Gasanz Garicochea, Isabel Martínez-Romera, Marta Pilar Osuna-Marco, Blanca López-Ibor Aliño","doi":"10.1136/ejhpharm-2022-003511","DOIUrl":null,"url":null,"abstract":"<p><p>The objective of the article is to report the case of three patients with diffuse intrinsic pontine glioma (DIPG) treated with immunotherapy. In particular we report the data related to the treatments' efficacy and tolerance.To achieve this, we review the medical records in the Paediatric Oncology and Haematology Unit of HM Hospitales/Centro Integral Oncológico Clara Campal (CIOCC). We focused on patients diagnosed with DIPG who were administered oncolytic viruses followed by immune checkpoint inhibitors (ICI) (pembrolizumab, anti PD-1) plus a concomitant antiangiogenic agent (bevacizumab).The results we obtained showed the three paediatric DIPG patients studied presented good tolerance, with disease stabilisation for approximately 5 months after immunotherapy. However, subsequent clinical worsening required clinicians to change the patients' treatment.In conclusion, immunotherapy combined with other conventional antineoplastic treatments (chemotherapy, radiotherapy) is postulated as a very promising future therapeutic option. However, further research is warranted in the paediatric population to demonstrate safety and effectiveness.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"190-192"},"PeriodicalIF":1.6000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of hospital pharmacy : science and practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/ejhpharm-2022-003511","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

The objective of the article is to report the case of three patients with diffuse intrinsic pontine glioma (DIPG) treated with immunotherapy. In particular we report the data related to the treatments' efficacy and tolerance.To achieve this, we review the medical records in the Paediatric Oncology and Haematology Unit of HM Hospitales/Centro Integral Oncológico Clara Campal (CIOCC). We focused on patients diagnosed with DIPG who were administered oncolytic viruses followed by immune checkpoint inhibitors (ICI) (pembrolizumab, anti PD-1) plus a concomitant antiangiogenic agent (bevacizumab).The results we obtained showed the three paediatric DIPG patients studied presented good tolerance, with disease stabilisation for approximately 5 months after immunotherapy. However, subsequent clinical worsening required clinicians to change the patients' treatment.In conclusion, immunotherapy combined with other conventional antineoplastic treatments (chemotherapy, radiotherapy) is postulated as a very promising future therapeutic option. However, further research is warranted in the paediatric population to demonstrate safety and effectiveness.

查看原文本刊更多论文

弥漫性桥脑胶质瘤患者免疫治疗的临床经验。

本文的目的是报告三例应用免疫疗法治疗弥漫性桥脑胶质瘤（DIPG）的病例。我们特别报告了与治疗效果和耐受性相关的数据。为了实现这一点，我们审查了英国皇家医院/Centro Integral Oncológico Clara Campal（CIOCC）儿科肿瘤和血液科的医疗记录。我们重点研究了被诊断为DIPG的患者，他们接受了溶瘤病毒治疗，然后接受了免疫检查点抑制剂（ICI）（pembrolizumab，抗PD-1）和伴随的抗血管生成剂（贝伐单抗）治疗。我们获得的结果显示，所研究的三名儿科DIPG患者表现出良好的耐受性，免疫治疗后疾病稳定约5个月。然而，随后的临床恶化需要临床医生改变患者的治疗方法。总之，免疫疗法结合其他常规抗肿瘤治疗（化疗、放疗）被认为是一种非常有前途的未来治疗选择。然而，有必要在儿科人群中进行进一步研究，以证明其安全性和有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European journal of hospital pharmacy : science and practice PHARMACOLOGY & PHARMACY-

CiteScore

3.40

自引率

5.90%

发文量

104

审稿时长

6-12 weeks

期刊介绍： European Journal of Hospital Pharmacy (EJHP) offers a high quality, peer-reviewed platform for the publication of practical and innovative research which aims to strengthen the profile and professional status of hospital pharmacists. EJHP is committed to being the leading journal on all aspects of hospital pharmacy, thereby advancing the science, practice and profession of hospital pharmacy. The journal aims to become a major source for education and inspiration to improve practice and the standard of patient care in hospitals and related institutions worldwide. EJHP is the only official journal of the European Association of Hospital Pharmacists.